Synapse - Wassim Abida

Results (154)

Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial

Journal Article

Nguyen, C. B.; Reimers, M. A.; Perera, C.; Abida, W.; Chou, J.; Feng, F. Y.; Antonarakis, E. S.; McKay, R. R.; Pachynski, R. K.; Zhang, J.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Phase I study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer progressing on enzalutamide

Journal Article

Abida, W.; Hahn, A. W.; Shore, N.; Agarwal, N.; Sieber, P.; Smith, M. R.; Dorff, T.; Monk, P.; Rettig, M.; Patel, R.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy

Journal Article

Walmsley, C. S.; Jonsson, P.; Cheng, M. L.; McBride, S.; Kaeser, C.; Vargas, H. A.; Laudone, V.; Taylor, B. S.; Kappagantula, R.; Baez, P.; more...
npj Precision Oncology (2024)

Fulltext@MSK | Save

Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)

Journal Article

Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
British Journal of Cancer (2024)

Fulltext@MSK | Save

Impact of PARP inhibitor and platinum therapy on clonal hematopoiesis

Meeting Abstract

Baeten, J. T.; Chan, I. C. C.; Moukarzel, L.; Carter, A. C.; Patel, M.; Stopsack, K. H.; Pharoah, P.; Brenton, J.; Li, B. T.; Abida, W.; more...
Blood (2023)

Fulltext@MSK | Save

Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer

Journal Article

Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
Journal of Immunotherapy and Precision Oncology (2023)

Fulltext@MSK | Save

A multi-center natural history study of precision-based genomics in prostate cancer (PC)

Meeting Abstract

Beltran, H.; Mateo, J.; Abida, W.; McKay, R. R.; Montgomery, R.t B.; Aggarwal, Rahul Raj; Lee-Wisdom, K.; Figg, W. D.; Dahut, W. L.; Karzai, F.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: Final results from the phase 2 TRITON2 study

Journal Article

Abida, W.; Campbell, D.; Patnaik, A.; Bryce, A. H.; Shapiro, J.; Bambury, R. M.; Zhang, J.; Burke, J. M.; Castellano, D.; Font, A.; more...
European Urology (2023)

Fulltext@MSK | Save

PARP inhibitors for prostate cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) blues

Editorial

Beije, N.; Abida, W.; Antonarakis, E. S.; Castro, E.; de Wit, R.; Fizazi, K.; Gillessen, S.; Hussain, M.; Mateo, J.; Morris, M. J.; more...
European Urology (2023)

Fulltext@MSK | Save

Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer

Editorial

Abida, W.; Attard, G.
Lancet (2023)

Fulltext@MSK | Save